Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up – Here’s What Happened

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares gapped up prior to trading on Thursday . The stock had previously closed at $12.72, but opened at $13.84. Bicara Therapeutics shares last traded at $12.96, with a volume of 26,795 shares.

Analysts Set New Price Targets

A number of research firms have issued reports on BCAX. HC Wainwright boosted their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock. Wedbush started coverage on shares of Bicara Therapeutics in a research note on Thursday. They set an “outperform” rating and a $31.00 price objective for the company. Finally, RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Trading Down 2.2 %

The business’s fifty day simple moving average is $16.00.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BCAX. Spire Wealth Management bought a new position in Bicara Therapeutics in the fourth quarter worth about $31,000. SG Americas Securities LLC bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth approximately $147,000. Cinctive Capital Management LP acquired a new position in Bicara Therapeutics during the 3rd quarter valued at approximately $229,000. Barclays PLC bought a new position in Bicara Therapeutics during the 3rd quarter worth $255,000. Finally, Jane Street Group LLC bought a new stake in Bicara Therapeutics in the third quarter valued at $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.